Advik Laboratories Ltd Stock Price Today (NSE: ADVIKLA)
Fundamental Score
Advik Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Advik Laboratories Ltd share price today is ₹1.90, up +0.00% on NSE/BSE as of 3 August 2026. Advik Laboratories Ltd (ADVIKLA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹3.63 (Cr). The 52-week high for ADVIKLA share price is ₹2.47 and the 52-week low is ₹1.57. The company has a Return on Equity (ROE) of -177.39% and a debt-to-equity ratio of 107.43.
Advik Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Advik Laboratories Ltd share price chart: 4.97% return over the past month. 52-week high ₹2.47, 52-week low ₹1.57.
Advik Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1.90 | ₹1.90 | ₹1.90 | ₹1.90 | 0.00 (Cr) | |
| ₹1.90 | ₹1.90 | ₹1.90 | ₹1.90 | 0.00 (Cr) | |
| ₹1.90 | ₹1.90 | ₹1.90 | ₹1.90 | 0.00 (Cr) | |
| ₹1.90 | ₹1.90 | ₹1.90 | ₹1.90 | 0.00 (Cr) | |
| ₹1.90 | ₹1.90 | ₹1.90 | ₹1.90 | 0.00 (Cr) | |
| ₹1.90 | ₹1.90 | ₹1.90 | ₹1.90 | 0.00 (Cr) | |
| ₹1.90 | ₹1.90 | ₹1.90 | ₹1.90 | 0.00 (Cr) | |
| ₹1.90 | ₹1.90 | ₹1.90 | ₹1.90 | 0.00 (Cr) | |
| ₹1.90 | ₹1.90 | ₹1.90 | ₹1.90 | 98.00 (Cr) | |
| ₹1.90 | ₹1.90 | ₹1.90 | ₹1.90 | 0.00 (Cr) |
Advik Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1.81 | ₹1.90 | ₹1.81 | ₹1.90 | +4.97% | |
| ₹1.73 | ₹1.81 | ₹1.71 | ₹1.81 | +4.62% | |
| ₹1.73 | ₹1.73 | ₹1.73 | ₹1.73 | +0.00% | |
| ₹1.73 | ₹1.73 | ₹1.73 | ₹1.73 | +0.00% | |
| ₹1.57 | ₹1.73 | ₹1.57 | ₹1.65 | +5.10% | |
| ₹1.76 | ₹1.76 | ₹1.60 | ₹1.65 | -6.25% | |
| ₹1.76 | ₹1.80 | ₹1.68 | ₹1.68 | -4.55% | |
| ₹1.77 | ₹1.85 | ₹1.76 | ₹1.85 | +4.52% | |
| ₹1.90 | ₹1.90 | ₹1.76 | ₹1.76 | -7.37% | |
| ₹2.08 | ₹2.08 | ₹1.99 | ₹1.99 | -4.33% | |
| ₹2.04 | ₹2.08 | ₹1.90 | ₹2.08 | +1.96% | |
| ₹2.47 | ₹2.47 | ₹2.14 | ₹2.14 | -13.36% |
AI Research Briefing
Powered by Gemini · 2026-08-01
Severely distressed micro-cap shell with ₹0.04 Cr annual revenue and severe debt burden, posing extreme capital loss risk.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. The latest financial data for FY2025-2026 shows full-year revenue collapsed to ₹0.04 Cr while net loss widened to ₹1.02 Cr, representing a net profit margin of -2550.00%. The Q4 FY2025-2026 quarterly revenue stood at a negligible ₹0.04 Cr. There are no recent order wins, expansion filings, or material corporate disclosures on the exchanges over the past month.
CORE STORY (THE REAL GAME)
This is not an operational pharmaceutical growth play; it is a micro-cap shell with virtually zero commercial turnover. With annual sales down to ₹0.04 Cr against operating expenses of ₹0.40 Cr, the business generates almost no active cash flows. The trade here is purely speculative micro-cap volatility rather than underlying earnings trajectory or pharmaceutical demand.
- No major catalysts found after live search for the last 2-4 weeks
- FY2025-2026 full-year revenue collapsed to ₹0.04 Cr with net loss at ₹1.02 Cr
- Debt-to-equity ratio remains stressed at 107.43 with negative ROE of -177.39%
- Promoter capital infusion or debt restructuring announcements
- Asset monetization or disposal of manufacturing units
- Speculative micro-cap momentum spikes driven by low floating stock
- Extreme micro/SME cap illiquidity risk making entry and exit difficult
- Promoter pledge stands high at 16.04% of total equity
- Negative 5-year Free Cash Flow of ₹-5.62 Cr with interest coverage non-existent
FII holds 0.0% (Δ 0.0%), DII holds 0.58% (Δ 0.0%), and Promoter holding stands flat at 35.9% (Δ 0.0%) with zero institutional accumulation.
Indian pharma sector benefits from government policy support, but micro-caps lacking operational scale fail to capture export or domestic tailwinds.
No — 5-year Free Cash Flow remains negative at ₹-5.62 Cr
High solvency and operational disruption risk over the next 3-6 months. Lacks basic revenue generation to cover fixed overheads.
Primary Thesis Risk
Complete operational paralysis and inability to service debt leading to equity erosion.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Advik Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Advik Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ADVIKLA across key market metrics for learning purposes.
Positive Indicators
0 factors identified
No significant strengths identified in current analysis.
Risk Factors
7 factors identified
Below-Average Return on Equity (-177.39%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-13.14%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-28.57%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Elevated Debt Levels (D/E: 107.43)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Negative Free Cash Flow (₹-5.62 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.58%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Advik Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Advik Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Advik Laboratories LtdAdvik Laborator...Selected✓ ADVIKLA • 531686 | 0/100 | ₹1.90₹2 | ₹3.63₹3.63 | — — | -177.39%Poor -177.39% Poor | -13.14%Poor -13.14% Poor | 107.43Poor 107.4 Poor | 12.20%Good 12.20% Good | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Advik Laboratories Ltd Quarterly Performance
Latest quarterly metrics for ADVIKLA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
N/A
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-28.57%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
12.20%
Compounded annual net profit growth over 5 years
Advik Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ADVIKLA — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Advik Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Advik Laboratories Ltd (ADVIKLA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Advik Laboratories Ltd
About ADVIKLA (Advik Laboratories Ltd)
Advik Laboratories Ltd is a research-driven pharmaceutical company dedicated to developing, manufacturing, and marketing innovative and high-quality medicines. Focusing on therapeu...tic areas with unmet medical needs, Advik Laboratories strives to improve patient outcomes and enhance the quality of life for individuals worldwide. The company's state-of-the-art research and development facilities are staffed by a team of experienced scientists and researchers who are committed to discovering and developing novel drug formulations. Advik Laboratories adheres to the highest ethical standards and regulatory requirements, ensuring the safety and efficacy of its products. With a strong emphasis on innovation, quality, and patient-centricity, Advik Laboratories is poised to make a significant impact on the global healthcare landscape. The company's robust product portfolio encompasses a wide range of therapeutic categories, including cardiovascular diseases, diabetes, oncology, and infectious diseases. Advik Laboratories leverages advanced technologies and innovative drug delivery systems to develop differentiated products that address specific patient needs. The company's manufacturing facilities are equipped with advanced technology and adhere to strict quality control measures to ensure that all products meet the highest standards of purity, safety, and efficacy. Advik Laboratories is committed to providing affordable and accessible medicines to patients around the world, partnering with healthcare professionals and organizations to improve access to care and promote better health outcomes. Advik Laboratories has established a strong global presence, with a network of distributors and partners in key markets around the world. The company's commitment to innovation, quality, and patient-centricity has earned it a reputation as a trusted and reliable partner in the pharmaceutical industry. Advik Laboratories is constantly seeking to expand its product portfolio and explore new therapeutic areas to address emerging healthcare needs. The company is dedicated to improving the lives of patients worldwide through the development and delivery of innovative and high-quality medicines. Advik Laboratories is driven by a passion for science, a commitment to innovation, and a desire to make a positive impact on global healthcare.
Company Details
Key Leadership
ADVIKLA Share Price: Frequently Asked Questions
What is the current share price of Advik Laboratories Ltd?
Advik Laboratories Ltd (ADVIKLA) trades at ₹1.90 on NSE and BSE. Market cap ₹3.63 (Cr). Educational data only.
What is the P/E ratio of Advik Laboratories Ltd?
Advik Laboratories Ltd has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Advik Laboratories Ltd?
Advik Laboratories Ltd has a Bull Run score of 0/100 based on 25+ financial parameters.
Does Advik Laboratories Ltd pay dividends?
Advik Laboratories Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Advik Laboratories Ltd?
Advik Laboratories Ltd has ROE of -177.39%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Advik Laboratories Ltd?
Advik Laboratories Ltd has debt-to-equity of 107.43.
Is Advik Laboratories Ltd a good investment?
Bull Run gives Advik Laboratories Ltd a score of 0/100. This is not investment advice — consult a SEBI-registered advisor.